21-hydroxylase

21-hydroxylase
source
Name	21-hydroxylase
EC number	1.14.14.16
CAS number	9029-68-9
Alt names	Steroid 21-monooxygenase, P450c21
Gene	CYP21A2

21-hydroxylase. It is a crucial enzyme encoded by the CYP21A2 gene, belonging to the cytochrome P450 superfamily. This protein catalyzes a vital step in the adrenal cortex, converting progesterone to 11-deoxycorticosterone and 17α-hydroxyprogesterone to 11-deoxycortisol, which are precursors for mineralocorticoid and glucocorticoid synthesis. Deficiency in this enzyme is the most common cause of congenital adrenal hyperplasia, a group of autosomal recessive disorders affecting adrenal steroidogenesis.

Function and mechanism

21-hydroxylase functions within the mitochondria of cells in the zona fasciculata and zona glomerulosa of the adrenal glands. Its primary biochemical role is to catalyze the 21-hydroxylation of steroid substrates, a reaction essential for producing cortisol and aldosterone. This hydroxylation reaction utilizes molecular oxygen and NADPH via the electron transfer chain involving adrenodoxin reductase and adrenodoxin. The enzyme's activity is integral to the steroidogenic pathway, ensuring proper synthesis of hormones that regulate blood pressure, immune response, and metabolism. Without this function, the pituitary gland increases secretion of adrenocorticotropic hormone in a futile attempt to stimulate cortisol production.

Clinical significance

Deficiency of 21-hydroxylase accounts for over 90% of all cases of congenital adrenal hyperplasia, a condition studied extensively at institutions like the National Institutes of Health. This deficiency disrupts normal adrenal steroidogenesis, leading to an accumulation of 17α-hydroxyprogesterone and a diversion of precursors into the androgen biosynthesis pathway. The resulting clinical spectrum ranges from the severe salt-wasting form, presenting with hyponatremia and hyperkalemia in infancy, to the milder simple virilizing and non-classical forms. These disorders can cause ambiguous genitalia in genetic females, precocious puberty, and infertility, with long-term management challenges documented in studies from the Mayo Clinic.

Genetics and biosynthesis

The gene responsible for 21-hydroxylase, CYP21A2, is located on chromosome 6p21.3 within the major histocompatibility complex region, adjacent to a non-functional pseudogene, CYP21A1P. Most pathogenic mutations result from microconversion events between the active gene and the pseudogene during meiosis. Common mutations include c.293-13A/C>G (intron 2 splice site), p.Ile172Asn, and large gene deletions. These genetic alterations lead to a spectrum of enzyme impairment, correlating with the clinical severity of congenital adrenal hyperplasia. Research from centers like the University of California, San Francisco has detailed the population genetics and variable prevalence among different ethnic groups.

Diagnosis and testing

Diagnosis of 21-hydroxylase deficiency involves a combination of clinical assessment and specialized laboratory testing. Newborn screening programs, pioneered in states like Texas and countries like Japan, measure elevated levels of 17α-hydroxyprogesterone in dried blood spots. Confirmatory testing includes detailed serum hormone analysis, such as renin and androstenedione levels, and ACTH stimulation test. Molecular genetic testing to identify mutations in the CYP21A2 gene is the definitive diagnostic method, often performed at reference laboratories like Quest Diagnostics. Prenatal diagnosis is possible via chorionic villus sampling or amniocentesis, and treatment can be initiated in utero to prevent virilization of affected female fetuses.

Management and treatment

Standard management of 21-hydroxylase deficiency involves lifelong glucocorticoid replacement, typically with hydrocortisone or prednisone, to suppress ACTH and reduce excess androgen production. The salt-wasting form requires mineralocorticoid replacement with fludrocortisone and increased sodium chloride intake. Treatment is monitored through regular assessments of growth velocity, bone age, and hormone levels like 17α-hydroxyprogesterone and plasma renin activity. In cases of severe ambiguous genitalia, surgical correction may be considered, guided by multidisciplinary teams at institutions such as Boston Children's Hospital. Emerging therapies, including gene therapy and CRISPR-Cas9 approaches, are under investigation at research centers like the Broad Institute.

Category:Enzymes Category:EC 1.14.14